Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L21 pseudogene 10 (RPL21P10) is a processed pseudogene related to the functional ribosomal protein L21 gene (RPL21). The functional RPL21 encodes a component of the large 60S ribosomal subunit involved in protein synthesis, but RPL21P10 itself is not translated into protein and does not have a known biological function. Pseudogenes are genetic elements that resemble genes but are generally non-functional due to the lack of regulatory elements or the presence of disabling mutations[1][3]. There is no evidence for RPL21P10 being a therapeutic target or having disease association, biomarkers, or drug interactions. This nomenclature follows the convention of ribosomal protein pseudogenes, which are numerous in the human genome and do not encode functional proteins. This entry is a pseudogene, not a protein-coding gene, receptor, enzyme, or therapeutic target. It should not be considered a drug target[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L21 pseudogene 10 (RPL21P10).